Senate Health Care Cost Transparency Initiative Doesn't Mention Drug Pricing, But Likely Can't Avoid It
Executive Summary
Bipartisan effort seems more focused on increasing cost transparency for US health care services, but stakeholders still are expected to raise drug pricing issues.
You may also be interested in...
Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue
To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.
Drug Pricing: PhRMA Report Aims To Shift Focus To Supply Chain
More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.
Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal
CEO Heather Bresch defended her company’s controversial decision to raise the price of the allergy medicine to $600 during the Forbes Healthcare Summit and even took questions from fellow pharma insiders like “Why did you ruin it?”